U.S., Jan. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07378527) titled 'Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria' on Jan. 23.
Brief Summary: The purpose of this study is to compare the efficacy and safety of ICP-332 in moderate to severe chronic spontaneous urticaria subjects inadequately controlled by second generation H1-antihistamines
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Chronic Spontaneous Urticaria (CSU)
Intervention:
DRUG: ICP-332 Tablets
ICP-332 will be administered as tablet for 12 weeks
DRUG: ICP-332 placebo Tablets
ICP-332 placebo will be administered as tablet for 12 weeks
DRUG: ICP-332 Tablets
ICP...